NEW YORK – JW Therapeutics on Tuesday announced a collaboration with 2seventy Bio to develop and commercialize a CAR T-cell therapy product for autoimmune diseases in greater China.
Under the agreement, JW will initiate process development and the first-in-human trials in China of the CAR T-cell therapy, and both firms will share the cost. JW is eligible to receive development, regulatory, and sales milestone payments totaling up to high-double-digit million US dollars and potential royalty payments on worldwide net sales of the product outside of greater China. The firm also has the right to negotiate for an exclusive license to develop, manufacture, and commercialize the product in greater China.
This collaboration is an extension of an earlier partnership between JW and 2seventy to establish a translational and clinical development platform to advance the development of T-cell-based immunotherapy products in China, Hong Kong, and Macao. That partnership, started in 2022, was originally focused on development of 2seventy's MAGE-A4 T-cell receptor program in solid tumors.
JW, based in Shanghai, has one cell therapy product in development for an autoimmune disease, a CD19-directed therapy for the treatment of systemic lupus erythematosus. The firm's pipeline also includes CAR T programs for lymphomas, multiple myeloma, and solid tumors.